Small Intestinal Adenocarcinoma With PTPRK :: RSPO3 Fusion: Clinicopathologic Characteristics, Molecular Landscape, and Disease Outcome of Five Patients

RSPO3 fusion activates the Wnt/β-catenin pathway at the level of upstream Wnt ligands, rather than directly through APC / CTNNB1 mutations. Beyond colorectal carcinoma, RSPO3 fusions remain underexplored. Herein, we report the first case series of PTPRK :: RSPO3 fusion-positive small intestinal adenocarcinoma. Among 115 genomically profiled small intestinal adenocarcinomas, 5 (4%) patients were identified, including 4 (80%) women and 1 (20%) man, aged 51 to 69 years (mean = 59), of African American (4/5; 80%) and White (1/5; 20%) ethnicity. Tumors arose from the jejunum (4/5; 80%) and duodenum (1/5; 20%), with a mean size of 4.7 cm. All tumors were adenocarcinoma, not otherwise specified, with mucinous features in 2/5 (40%), presenting at pT4 with lymphovascular and perineural invasion, and were mismatch repair-proficient/microsatellite stable, ERBB2 (HER2)-negative, and PD-L1 (CD274)-negative, with low tumor mutation burden and loss of heterozygosity. All fusion transcripts resulted from an in-frame PTPRK exon 1:: RSPO3 exon 2 fusion. The molecular landscape demonstrated frequent mutations in TP53 (5/5 [100%]) and the MAPK pathway genes ( KRAS , NRAS , BRAF ; 4/5 [80%]), while being APC / CTNNB1 / RNF43 -wild-type. Despite multimodal therapy, all patients developed metastasis (peritoneum 5/5 [100%]; liver 4/5 [80%]), with a mean overall survival of 28.5 months. PTPRK :: RSPO3 fusion defines a subset of small intestinal adenocarcinomas that shares a core molecular profile with its colorectal counterpart, exhibits aggressive behavior, and is a candidate for emerging Wnt-targeted therapies. Including RNA-based testing in the molecular profiling of small intestinal adenocarcinoma can identify rare yet targetable fusion genes that may inform patient selection for clinical trials.

Authors

Institutions

Publication Details

Journal
International Journal of Surgical Pathology
Published
2026-11-17
DOI
https://doi.org/10.1177/10668969261495964
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Small Intestinal Adenocarcinoma With PTPRK :: RSPO3 Fusion: Clinicopathologic Characteristics, Molecular Landscape, and Disease Outcome of Five Patients

Haider A. Mejbel, Wen‐Yu Hsiao, Yulin Haw
International Journal of Surgical Pathology
Pancreatic and Hepatic Oncology Research
article

Small Intestinal Adenocarcinoma With PTPRK :: RSPO3 Fusion: Clinicopathologic Characteristics, Molecular Landscape, and Disease Outcome of Five Patients

Haider A. Mejbel, Wen‐Yu Hsiao, Yulin Haw
article en

Abstract

RSPO3 fusion activates the Wnt/β-catenin pathway at the level of upstream Wnt ligands, rather than directly through APC / CTNNB1 mutations. Beyond colorectal carcinoma, RSPO3 fusions remain underexplored. Herein, we report the first case series of PTPRK :: RSPO3 fusion-positive small intestinal adenocarcinoma. Among 115 genomically profiled small intestinal adenocarcinomas, 5 (4%) patients were identified, including 4 (80%) women and 1 (20%) man, aged 51 to 69 years (mean = 59), of African American (4/5; 80%) and White (1/5; 20%) ethnicity. Tumors arose from the jejunum (4/5; 80%) and duodenum (1/5; 20%), with a mean size of 4.7 cm. All tumors were adenocarcinoma, not otherwise specified, with mucinous features in 2/5 (40%), presenting at pT4 with lymphovascular and perineural invasion, and were mismatch repair-proficient/microsatellite stable, ERBB2 (HER2)-negative, and PD-L1 (CD274)-negative, with low tumor mutation burden and loss of heterozygosity. All fusion transcripts resulted from an in-frame PTPRK exon 1:: RSPO3 exon 2 fusion. The molecular landscape demonstrated frequent mutations in TP53 (5/5 [100%]) and the MAPK pathway genes ( KRAS , NRAS , BRAF ; 4/5 [80%]), while being APC / CTNNB1 / RNF43 -wild-type. Despite multimodal therapy, all patients developed metastasis (peritoneum 5/5 [100%]; liver 4/5 [80%]), with a mean overall survival of 28.5 months. PTPRK :: RSPO3 fusion defines a subset of small intestinal adenocarcinomas that shares a core molecular profile with its colorectal counterpart, exhibits aggressive behavior, and is a candidate for emerging Wnt-targeted therapies. Including RNA-based testing in the molecular profiling of small intestinal adenocarcinoma can identify rare yet targetable fusion genes that may inform patient selection for clinical trials.

International Journal of Surgical Pathology
Emory University (US), Winship Cancer Institute (US)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon